Amphastar Pharmaceuticals, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Dimensional Fund Advisors LP has disclosed a beneficial ownership stake of 5.2% in Amphastar Pharmaceuticals Inc., holding 2,305,107 shares.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G for Amphastar Pharmaceuticals Inc., reporting zero beneficial ownership following an internal realignment.
NASDAQ
BlackRock, Inc. has reported an increased beneficial ownership of 11.5% in Amphastar Pharmaceuticals, Inc., holding 5,333,463 shares of common stock.
NASDAQ
SCHEDULE 13G/A: Amphastar Pharmaceuticals Insiders Disclose Combined 24.8% Stake in Latest SEC Filing
Jack Y. Zhang, Mary Z. Luo, and Applied Physics & Chemistry Laboratories, Inc. (APCL) have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 24.8% of Amphastar Pharmaceuticals, Inc.'s common stock as of December 31, 2024.